Orthocell Details Path to Breakeven as US Remplir Sales Hit $300K in Q3
Orthocell reports 45% revenue growth as US Remplir sales gain traction
In its April 2026 investor presentation, Orthocell Limited outlined year-to-date revenue of $9.4 million for the first nine months of FY26, already exceeding the company’s full-year FY25 revenue of $9.2 million and representing 45% growth on the prior corresponding period. Management highlighted US revenue reaching $300,000 for Q3 FY26, described as the first material quarter of US sales, whilst the company achieved broadly breakeven operating cash flow with cash reserves of $48 million providing a 4.6-year runway.
Q3 FY26 revenue came in at $3.2 million, with US commercial metrics demonstrating compound quarterly growth across hospital approvals, surgeon adoption, and unit sales since the first Remplir transaction on 26 June 2025. The presentation detailed how nine months of commercialisation activity have transitioned from launch phase to revenue-generating operations, with financial metrics now supporting the company’s breakeven thesis.
When big ASX news breaks, our subscribers know first
What is Remplir and why does it matter for nerve repair?
Remplir is a collagen-based medical device designed for peripheral nerve repair in patients requiring surgical intervention following nerve injuries. The product addresses a clinical problem where damaged nerves require reconstruction to restore function, with traditional repair methods often limited by material availability and handling characteristics.
Orthocell’s platform spans bone, nerve and tendon repair applications, with products approved across nine jurisdictions. Manufacturing and intellectual property are retained in-house at the company’s Perth facility, supporting product margins whilst providing control over supply chain and quality systems.
Understanding the product helps investors appreciate why hospital and surgeon adoption metrics translate to recurring revenue potential across a large, underpenetrated market where treatment options have historically been constrained by material and technical limitations.
US commercial metrics demonstrate rapid early-stage adoption
Management presented compound quarterly growth rates across all key US metrics since the first sale on 26 June 2025, with 55 hospitals completing at least one sale and 115 hospitals approved to use Remplir as of 31 March 2026. The presentation outlined how the pipeline nature of VAC approvals creates a pathway to future sales, with approved hospitals representing accessible surgeon networks that have yet to convert to active usage.
| Metric | Q3 FY26 | CQGR Since Launch |
|---|---|---|
| Hospitals with sales | 55 | +275% |
| Approved hospitals | 115 | — |
| Active surgeons | 49 | +264% |
| Units sold (quarter) | 115 | +328% |
The company reported 16 distributors currently engaged, with 89 VAC submissions completed and 32 VAC approvals achieved. The presentation highlighted that the current VAC pipeline of 115 approved hospitals already exceeds the surgeon count required for breakeven, providing visibility on the path to profitability without requiring market share expansion beyond accessible hospital networks.
Defence sector adoption builds real-world evidence
Management spotlighted growing defence applications as validation of Remplir’s clinical utility, with approval secured across 221 US military medical centres. The presentation detailed 23 soldiers treated in Ukraine, demonstrating transportability and handling characteristics under field conditions where traditional nerve repair materials face logistical constraints.
The company completed its first case at a US military hospital during the quarter, with the existing distributor network now able to engage directly with military surgeons through established defence procurement channels. Defence applications represent a differentiated sales channel with potential for bulk procurement and high-profile clinical evidence that supports broader commercial adoption narratives.
Path to profitability requires less than 1% US market share
Management outlined the breakeven equation explicitly in the presentation, with current cash reserves of $48 million and normalised operating cash burn of $2.6 million for Q3 FY26 representing a 47% improvement on Q2. The company emphasised that the 300-400 surgeons required for breakeven are already accessible through the current VAC pipeline, with no additional funding required to reach profitability.
The breakeven calculation proceeds as follows:
- Breakeven requires approximately 5,000-6,000 US procedures annually
- This equates to roughly 10,000 units sold, based on an average of 1.7 units per procedure
- Requires 300-400 active surgeons performing approximately 18 procedures per year
- Represents less than 1% of the US peripheral nerve procedure market
The presentation positioned current cash reserves as sufficient to reach breakeven without additional funding, with the 4.6-year cash runway based on normalised operating cash burn providing substantial buffer against execution risk. The surgeon recruitment pipeline already provides line-of-sight to required adoption levels, with hospital approvals converting to active surgeon usage over time as training programmes and clinical experience accumulate.
Quarterly cash flow performance
Q3 achieved broadly breakeven operating cash flow, representing a $5.9 million improvement on Q2 FY26. The result reflected receipt of a $3.0 million R&D tax refund alongside higher customer receipts, which increased 33% quarter-on-quarter to $1.6 million.
Normalised operating cash burn of $2.6 million for the quarter excludes the R&D tax refund and one-off expenditure items, demonstrating underlying improvement in operational efficiency as the US commercialisation ramp continues. The presentation outlined how sustained cash reserves support the business to cash flow breakeven with no additional funding required, providing execution runway to convert the existing VAC pipeline into revenue-generating surgeon relationships.
Geographic expansion and pipeline catalysts ahead
Management outlined multiple near-term catalysts that could expand Remplir’s addressable market beyond the core US peripheral nerve opportunity:
- Canada: First sale imminent following distributor appointments completed during the quarter
- UK: LEDA Orthopaedics appointed as exclusive distributor; market development activities underway ahead of launch
- EU/UK regulatory: Clearance expected 2H CY26 following submissions lodged in prior quarters
- Prostate application: Approximately 200 prostatectomies performed; initial data expected 1H CY26 following academic publication
The presentation detailed strong performance in Australia and New Zealand since launch, with 314 surgeons actively using the product across 224 hospitals. Management reported near 100% year-on-year growth in the ANZ market, demonstrating sustained adoption in the company’s home geography whilst US commercialisation scales.
Geographic expansion provides multiple pathways to revenue diversification, with regulatory clearances in the UK and EU opening markets where existing clinical evidence from Australia and the US can accelerate surgeon adoption curves. The prostate application represents a distinct indication expansion within existing approved geographies, with academic publication providing independent validation of clinical utility.
The next major ASX story will hit our subscribers first
CY2026 execution priorities
Management outlined three focus areas for continued US growth, providing measurable milestones for investors to track execution against stated objectives:
- Commercial channel: Onboard regional sales directors for national coverage; 16 distributors currently engaged with further expansion planned to complete geographic coverage in high-volume states
- Hospital approvals: Target 75 additional VAC submissions and 25 additional VAC approvals by December 2026, building on the 89 submissions and 32 approvals achieved as of 31 March
- Surgeon adoption: Train 200+ additional surgeons; target 50+ new surgeons utilising Remplir, expanding the base of 49 surgeons currently performing procedures
The defined action plan provides a framework for assessing whether the company is converting its VAC pipeline into active revenue-generating relationships at the pace required to reach breakeven within the stated cash runway. Progress against these metrics will determine whether the less than 1% market share thesis remains achievable without additional capital.
Don’t Miss the Next Healthcare Breakout
Join 20,000+ investors receiving FREE breaking ASX healthcare news and in-depth analysis delivered within minutes of release. Get market-moving announcements the moment they drop by clicking the “Free Alerts” button at Big News Blast. Stay ahead on emerging healthcare opportunities before the broader market reacts.